A PHASE II STUDY OF PRERADIOTHERAPY CHEMOTHERAPY FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK MEDULLOBLASTOMA/PRIMITIVE NEUROECTODERMAL TUMOR: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (CCG 9931) Article

Allen, Jeffrey, Donahue, Bernadine, Mehta, Minesh et al. (2009). A PHASE II STUDY OF PRERADIOTHERAPY CHEMOTHERAPY FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK MEDULLOBLASTOMA/PRIMITIVE NEUROECTODERMAL TUMOR: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (CCG 9931) . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(4), 1006-1011. 10.1016/j.ijrobp.2008.09.019

Open Access

cited authors

  • Allen, Jeffrey; Donahue, Bernadine; Mehta, Minesh; Miller, Douglas C; Rorke, Lucy B; Jakacki, Regina; Robertson, Patricia; Sposto, Richard; Holmes, Emi; Vezina, Gilbert; Muraszko, Karin; Puccetti, Diane; Prados, Michael; Chan, Ka-Wah

sustainable development goals

authors

publication date

  • July 15, 2009

webpage

published in

keywords

  • ADJUVANT CHEMOTHERAPY
  • BRAIN-TUMORS
  • CANCER
  • CARBOPLATIN
  • CHILDHOOD MEDULLOBLASTOMA
  • CRANIOSPINAL RADIATION-THERAPY
  • Hyperfractionated radiotherapy
  • Life Sciences & Biomedicine
  • Medulloblastoma (high risk)
  • Oncology
  • PNET
  • PRERADIATION CHEMOTHERAPY
  • PROGNOSTIC-FACTORS
  • Preradiation chemotherapy
  • Radiology, Nuclear Medicine & Medical Imaging
  • Science & Technology
  • THYROID-DYSFUNCTION
  • YOUNG-ADULTS

Digital Object Identifier (DOI)

publisher

  • ELSEVIER SCIENCE INC

start page

  • 1006

end page

  • 1011

volume

  • 74

issue

  • 4